Targeting cytochrome P450 46A1 and brain cholesterol 24-hydroxylation to treat neurodegenerative diseases

Exploration of Neuroprotective Therapy

Irina A. Pikuleva¹ 

[1] Department of Ophthalmology and Visual Sciences, Case Western Reserve University, Cleveland, OH 44106, USA;

关键词: cytochrome p450 46a1;    24-hydroxycholesterol;    brain;    cholesterol turnover;    mevalonate pathway;    sterol flux;    acetyl-coenzyme a;   

DOI  :  10.37349/ent.2021.00013

来源: DOAJ

【 摘 要 】

The brain cholesterol content is determined by the balance between the pathways of in situ biosynthesis and cholesterol elimination via 24-hydroxylation catalyzed by cytochrome P450 46A1 (CYP46A1). Both pathways are tightly coupled and determine the rate of brain cholesterol turnover. Evidence is accumulating that modulation of CYP46A1 activity by gene therapy or pharmacologic means could be beneficial in the case of neurodegenerative and other brain diseases and affect brain processes other than cholesterol biosynthesis and elimination. This minireview summarizes these other processes, most common of which include abnormal protein accumulation, memory, and cognition, motor behavior, gene transcription, protein phosphorylation as well as autophagy and lysosomal processing. The unifying mechanisms, by which these processes could be affected by CYP46A targeting are also discussed.

【 授权许可】

Unknown